E Fund Management Co. Ltd. Has $210,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

E Fund Management Co. Ltd. increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,053 shares of the company’s stock after buying an additional 1,634 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Intellia Therapeutics were worth $210,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Whipplewood Advisors LLC bought a new stake in Intellia Therapeutics during the fourth quarter worth $40,000. Jones Financial Companies Lllp increased its stake in shares of Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares during the last quarter. KBC Group NV raised its holdings in shares of Intellia Therapeutics by 62.4% in the 4th quarter. KBC Group NV now owns 6,093 shares of the company’s stock valued at $71,000 after purchasing an additional 2,340 shares during the period. AdvisorNet Financial Inc raised its holdings in shares of Intellia Therapeutics by 96.4% in the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock valued at $118,000 after purchasing an additional 4,950 shares during the period. Finally, LMG Wealth Partners LLC acquired a new stake in Intellia Therapeutics in the 4th quarter valued at about $130,000. 88.77% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

NTLA has been the topic of a number of recent analyst reports. Citigroup boosted their price target on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. Wells Fargo & Company cut their price target on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Morgan Stanley cut shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Finally, Oppenheimer dropped their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.56.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $10.35 on Monday. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -1.90 and a beta of 1.97. Intellia Therapeutics, Inc. has a fifty-two week low of $8.30 and a fifty-two week high of $32.00. The stock has a fifty day moving average price of $10.61 and a 200-day moving average price of $15.07.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 29,000 shares of company stock valued at $352,551 over the last quarter. 3.20% of the stock is owned by company insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.